肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
10期
670-672,676
,共4页
赵园园%郗彦凤%杨宣琴%田树雄%吕楠%崔嵛
趙園園%郗彥鳳%楊宣琴%田樹雄%呂楠%崔崳
조완완%치언봉%양선금%전수웅%려남%최유
14-3-3 ε蛋白%膀胱尿路上皮癌%生物学标记
14-3-3 ε蛋白%膀胱尿路上皮癌%生物學標記
14-3-3 ε단백%방광뇨로상피암%생물학표기
14-3-3ε protein%Bladder urothelial carcinoma%Biological markers
目的 探讨14-3-3 ε蛋白在膀胱尿路上皮癌(Buc)中的表达及其临床病理意义.方法 采用免疫组织化学EnVision法检测14-3-3 ε蛋白在10例癌旁组织、25例低度恶性Buc[包括5例乳头状瘤、10例具有低度恶性潜能的尿路上皮癌(PUNLMP)、10例低级别尿路上皮癌]、21例高度恶性Buc(包括11例高级别尿路上皮癌、10例浸润性癌)中的定位及表达,并分析其与各临床指标的关系.结果 14-3-3 ε蛋白阳性着色部位为细胞质,癌旁组织阳性表达率为90.0％(9/10),低度恶性Buc为72.0％(18/25),高度恶性Buc为14.3％(3/21),其表达量随病理分级增高而降低,而与其他临床病理参数无相关性.高度恶性Buc与低度恶性Buc间、高度恶性Buc与癌旁组织间阳性表达率差异均有统计学意义(均P＜0.05).结论 14-3-3 ε蛋白的表达在膀胱癌的发生、发展中发挥着重要的作用,14-3-3 ε有可能是Buc早期诊断及“两类癌”分类的一个生物学标志物,具有潜在的临床应用价值.
目的 探討14-3-3 ε蛋白在膀胱尿路上皮癌(Buc)中的錶達及其臨床病理意義.方法 採用免疫組織化學EnVision法檢測14-3-3 ε蛋白在10例癌徬組織、25例低度噁性Buc[包括5例乳頭狀瘤、10例具有低度噁性潛能的尿路上皮癌(PUNLMP)、10例低級彆尿路上皮癌]、21例高度噁性Buc(包括11例高級彆尿路上皮癌、10例浸潤性癌)中的定位及錶達,併分析其與各臨床指標的關繫.結果 14-3-3 ε蛋白暘性著色部位為細胞質,癌徬組織暘性錶達率為90.0％(9/10),低度噁性Buc為72.0％(18/25),高度噁性Buc為14.3％(3/21),其錶達量隨病理分級增高而降低,而與其他臨床病理參數無相關性.高度噁性Buc與低度噁性Buc間、高度噁性Buc與癌徬組織間暘性錶達率差異均有統計學意義(均P＜0.05).結論 14-3-3 ε蛋白的錶達在膀胱癌的髮生、髮展中髮揮著重要的作用,14-3-3 ε有可能是Buc早期診斷及“兩類癌”分類的一箇生物學標誌物,具有潛在的臨床應用價值.
목적 탐토14-3-3 ε단백재방광뇨로상피암(Buc)중적표체급기림상병리의의.방법 채용면역조직화학EnVision법검측14-3-3 ε단백재10례암방조직、25례저도악성Buc[포괄5례유두상류、10례구유저도악성잠능적뇨로상피암(PUNLMP)、10례저급별뇨로상피암]、21례고도악성Buc(포괄11례고급별뇨로상피암、10례침윤성암)중적정위급표체,병분석기여각림상지표적관계.결과 14-3-3 ε단백양성착색부위위세포질,암방조직양성표체솔위90.0％(9/10),저도악성Buc위72.0％(18/25),고도악성Buc위14.3％(3/21),기표체량수병리분급증고이강저,이여기타림상병리삼수무상관성.고도악성Buc여저도악성Buc간、고도악성Buc여암방조직간양성표체솔차이균유통계학의의(균P＜0.05).결론 14-3-3 ε단백적표체재방광암적발생、발전중발휘착중요적작용,14-3-3 ε유가능시Buc조기진단급“량유암”분류적일개생물학표지물,구유잠재적림상응용개치.
Objective To investigate the expression of 14-3-3ε protein in the bladder urothelial carcinoma (BUC) and to explore its association with the clinicopathologic features.Methods The bladder urothelial carcinoma samples were divided into three groups:normal control group of 10 cases,low-grade malignant BUC group of 25cases (includes 5 cases of papilloma,10 cases of PUNLMP and 10 cases of low grade non-invasive papillary urothelial carcinoma),high-grade malignant BUC group of 21 cases (includes 11 cases of high-grade non invasive papillary urothelial carcinoma and 10cases of infiltrating carcinoma).The expression and location of 14-3-3ε in three groups were detected by immunohistochemical EnVision and the relationship with clinicopathologic parameters was analyzed.Results 14-3-3ε expression was observed in the cytoplasm of the cell.The expression of 14-3-3ε in normal control group was 90 ％ (9/10),low-grade malignant BUC group was 72.0 ％ (18/25),high grade malignant BUC group was 14.3 ％ (3/21).It correlated with histological grading but had not showed correlation with other clinicopathologic parameters.There was significant difference in 14-3-3ε expression between the high grade malignant BUC group and the low-grade malignant BUC group,the high grade malignant BUC group and norml control group (all P ＜ 0.05).Conclusions 14-3-3ε plays an important role in carcinogenesis of BUC.It may be a biomarker for early diagnosis and classification of BUC and shows promise for clinic application.
